TapImmune Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients
June 23, 2015
Phase I Trial analyses shows safety and positive immune response data
SEATTLE, June 23, 2015 /PRNewswire/ – TapImmune Inc. (TPIV) is pleased to report the completion of data analysis from patients treated in a Phase I clinical trial. In this Phase 1 trial conducted at the Mayo Clinic in Rochester, MN, women diagnosed with HER2+ breast cancer (Stages II-III) that had completed standard treatment (i.e. surgery, chemotherapy, and Herceptin™) at least 90 days prior to enrollment were declared disease free and were treated with a multi-peptide HER2/neu vaccine. Twenty-two subjects (age 33 to 69 years) were enrolled. Patients were injected six times over six months with the multi-peptide vaccine and were monitored for toxicity during each visit. Twenty-one patients completed all 6 vaccination cycles. Vaccine induced T-cell immunity was observed in 19 out of 20 evaluable patients.
Dr. Glynn Wilson, TapImmune’s CEO stated “We are excited by the Phase I results of our HER2/neu vaccine trial. The potential to treat ~85% of breast cancer patients with this HER2/neu therapeutic approach is significant. The successful completion of this HER2/neu vaccine Phase I study and the robust immune responses detected provides TapImmune with a second Phase II clinical candidate and an expanded clinical pipeline for the treatment of breast and ovarian cancer. It also further validates the technology and the approach developed at Mayo Clinic by Professor Keith Knutson.”
The Company recently announced the results of a successful Phase I trial on a Folate Receptor Alpha Vaccine in ovarian and triple negative breast cancer and progression of this program into Phase II clinical trials. TapImmune has an exclusive option to license both the HER2/neu and Folate Receptor Alpha vaccine technologies from Mayo Clinic.
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient’s killer T-cells and helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing). The Company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at markertherapeutics.com for details.
Forward-Looking Statement Disclaimer: This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements
Glynn Wilson, Ph.D.
Chairman & CEO
Kirin M. Smith
Chief Operating Officer
Chief Communications Officer
J. Streicher Capital, LLC
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-reports-robust-immune-responses-generated-in-19-of-20-evaluable-her2neu-breast-cancer-patients-300103197.html